Central to this study is the demonstration that genetic ancestry profoundly impacts how patients respond to therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly prescribed for weight loss and type 2 diabetes. The researchers found that therapeutic efficacy of GLP-1 drugs, such as semaglutide, varies significantly across different ancestral populations, and critically, this variability correlates with individuals’ genetic risk scores for type 2 diabetes. Such findings underscore the limitations of one-size-fits-all treatment approaches and herald a new era where genetic insights inform tailored medical interventions.

Utilizing integrative proteogenomic analyses, the team pinpointed a key genetic association between response to semaglutide and the gene PTPRU. This gene had not previously been linked to GLP-1 drug response, offering compelling evidence for its role in modulating treatment outcomes. Proteomics data from patients undergoing GLP-1 therapy further reinforced these findings, providing a molecular bridge between genotypic variation and phenotypic drug responsiveness. This discovery paves the way for future mechanistic studies and the potential development of predictive biomarkers to optimize obesity and diabetes therapies.

The ATLAS Biobank uniquely encompasses an expansive representation of ancestries, reflecting Los Angeles’ unparalleled ethnic diversity. Participants hail from five continental ancestries and encompass thirty-six fine-scale ancestry groups, including communities historically underrepresented in genetic research such as Armenian, Ashkenazi Jews, Iranian Jewish, Filipino, and Mexican American populations. This breadth allows for the disentanglement of genetic influences on health outcomes without confounding by healthcare system disparities, a common challenge when comparing data across institutions.

Historically, the majority of genomic studies have disproportionately sampled populations of European descent, limiting the applicability of findings to the global population and exacerbating health disparities. The UCLA ATLAS initiative confronts this bias head-on by drawing from one of the world’s most ancestrally diverse metropolitan areas—Los Angeles County—which boasts over 9.6 million residents. By integrating diverse genetic data with longitudinal clinical records within a single health system, this study establishes a paradigm for equitable precision medicine research.

Beyond common genetic variants, the study pioneers examination of rare variants within specific ancestry groups, unveiling hitherto unknown genetic correlations with disease phenotypes. For instance, the gene ANKZF1 was linked to peripheral vascular disease among African ancestry individuals, while EPG5 was associated with lipid metabolism traits such as HDL cholesterol and triglyceride levels in Ashkenazi Jewish participants. These discoveries highlight the importance of including rare variant analyses in multi-ancestry cohorts to illuminate genetic contributions to complex diseases.

The investigation also delineated ancestry-specific susceptibilities to adverse drug reactions. Among Mexicans and South Americans, increased vulnerability to negative hormonal therapy effects was observed, reinforcing the need for ancestry-informed pharmacovigilance. This awareness is critical for improving drug safety profiles and optimizing treatment plans for diverse populations, thereby enhancing patient outcomes and reducing health inequities.

A further significant dimension of the research involves polygenic risk scores (PRS), composite metrics summarizing genetic predispositions to diseases based on numerous variants spread across the genome. Within the ATLAS cohort, PRS demonstrated promising predictive power for conditions like type 1 diabetes, with a substantial proportion of patients exhibiting elevated scores matching their clinical diagnoses. Though clinical translation remains in early stages, these findings position PRS as a valuable tool for stratifying patient risk and guiding preventive strategies.

The researchers’ focus on GLP-1 receptor agonists as a case study showcases how genetic diversity can influence response to commonly prescribed medications. GLP-1 drugs, including branded agents such as Ozempic and Wegovy, have revolutionized treatment for obesity and diabetes but exhibit variable efficacy among individuals. Identifying genetic markers like those in PTPRU provides a molecular rationale for this heterogeneity and suggests pathways to develop predictive algorithms to personalize therapy.

Importantly, the UCLA Health system’s comprehensive real-world data environment—linking genetics with electronic health records—affords robust insights into disease pathogenesis and therapeutic outcomes within a clinical context. This approach contrasts with isolated laboratory investigations, elevating the translational potential of discoveries. As Dr. Daniel Geschwind, senior associate dean of Precision Health at UCLA, notes, ATLAS’s integration of broad and fine-scale ancestries illuminates genetic factors overlooked in earlier studies focused on broad ancestral categories alone.

Already, the ATLAS Biobank supports a public web portal presenting thousands of heritable genetic associations across diverse populations, enabling researchers worldwide to access and build upon these unprecedented data. With over 259,000 participants consented and 157,000 biospecimens collected since its launch in 2016, this initiative embodies a scalable model for genomic medicine research embedded within large health systems, fostering health equity by design.

The implications of these findings extend far beyond the academic sphere. They propel precision medicine closer to practical application, where individual genomic profiles guide risk assessment, diagnosis, and personalized treatments. Furthermore, this study is a call to action emphasizing the necessity of inclusive genetic research that respects and reflects population diversity to fulfill the promise of equitable, effective healthcare for all.

In conclusion, the UCLA Health-led study published in Cell underscores the transformative impact of integrating genetic diversity, clinical data, and molecular biology within a single health ecosystem. It highlights novel genetic determinants influencing disease risk and drug response, particularly in relation to type 2 diabetes and weight loss medications. By bridging gaps in ancestry representation and leveraging comprehensive real-world data, the work sets a new standard for precision health discovery and clinical translation, demonstrating that personalized medicine is not just a possibility for some but an achievable goal for the global population.

Subject of Research: Human tissue samples
Article Title: Advancing Precision Health Discovery in a Genetically Diverse Health System
News Publication Date: 27-Mar-2026
Web References: [UCLA ATLAS Community Health Initiative Biobank Web Portal] (link not provided in source)
References: DOI: 10.1016/j.cell.2026.03.007
Keywords: precision medicine, genetic diversity, GLP-1 receptor agonists, type 2 diabetes, polygenic risk scores, ancestry, genetic associations, semaglutide, pharmacogenomics, health disparities, rare genetic variants, proteomics

The therapeutic landscape for type 2 diabetes increasingly emphasizes cardiovascular and renal risk reduction, recognizing that glycemic control alone is insufficient to prevent the morbid complications of the disease. GLP-1 RAs have emerged as pivotal agents, with various large-scale randomized trials supporting their capacity to reduce major adverse cardiovascular events (MACE) and slow progression of diabetic nephropathy. Liraglutide, semaglutide, and dulaglutide, each with distinct molecular profiles and pharmacokinetics, have demonstrated individually robust efficacy, but direct comparative data have been limited, necessitating investigations such as this to inform clinical decision-making.

This particular study leveraged the Veterans Health Administration database, enabling access to extensive longitudinal patient data. The analysis incorporated advanced statistical techniques designed to emulate randomized treatment comparisons through careful adjustment of confounding variables. The veteran population window, characterized by a predominantly male cohort with substantial cardiovascular disease burden, offers a real-world context that complements the more selective patient populations enrolled in traditional randomized controlled trials.

Intriguingly, after controlling for baseline patient characteristics and co-medications, the risk of cardiovascular endpoints such as myocardial infarction, stroke, and heart failure hospitalization did not differ significantly between patients initiating liraglutide versus semaglutide or dulaglutide. Similarly, renal outcomes, including progression to end-stage kidney disease or significant decline in estimated glomerular filtration rate, were comparable across these drug initiators. These findings reinforce the clinical equipoise among these particular GLP-1 RA agents in mitigating diabetes-related cardiorenal complications.

While randomized clinical trials represent the gold standard for determining causality between interventions and outcomes, the logistical and ethical complexities inherent in such trials, especially comparing already approved medications, have limited direct comparisons. Observational comparative effectiveness studies like this one employ sophisticated analytic methods such as propensity score matching and inverse probability weighting to mimic randomization, which although cannot fully eliminate unmeasured confounding, provide valuable and timely evidence with pragmatic relevance.

The heterogeneity in molecule structure between liraglutide, semaglutide, and dulaglutide—ranging from differences in receptor binding affinity to dosing frequency—may theoretically translate into variable clinical effects. However, the study’s findings suggest that these pharmacological differences do not tangibly alter medium-term cardiorenal outcomes in practice. This equivalency may provide clinicians with latitude to tailor treatment based on patient preferences, tolerability, cost, and route of administration without compromising efficacy.

Moreover, the findings have implications for health system formulary decisions, potentially alleviating pressure to favor any one particular agent purely based on perceived superiority in cardiovascular or renal risk mitigation. In resource-constrained environments, such flexibility can enable broader access to GLP-1 RAs, accelerating uptake of these beneficial therapies in populations that historically experience high rates of diabetic complications.

Nonetheless, the authors prudently highlight the need for prospective randomized head-to-head trials to definitively substantiate this apparent parity in clinical effectiveness. Such trials would provide more granular insight into long-term safety, differential effects in diverse demographic and clinical subgroups, and potential mechanistic distinctions that could inform personalized medicine approaches in diabetes care.

The study also underscores the critical importance of studying real-world outcomes beyond glycemic indices alone. As diabetes treatment evolves, cardiovascular and renal protection have shifted from being ancillary benefits to central therapeutic targets. A growing consensus posits that optimizing drug selection on these clinical endpoints, supported by robust comparative effectiveness data, constitutes best practice in the evolving paradigm of holistic diabetes management.

It is essential to note that this study focused on a predominantly male veteran population with substantial comorbidities, which may limit generalizability to the broader, more diverse patient populations. Further research in women, different ethnic groups, and patients with varying disease severity is warranted to confirm these results and enhance inclusivity.

In conclusion, this comprehensive comparative study provides compelling evidence that liraglutide, semaglutide, and dulaglutide demonstrate similar effectiveness in reducing cardiovascular and kidney risks in veterans with type 2 diabetes. Clinicians can consider these agents as broadly equivalent options pending further head-to-head trials. Such data empower informed therapeutic choices, balancing efficacy with patient-centered factors, and ultimately improving outcomes in a population burdened by multi-system diabetic complications.

The evolution of diabetes pharmacotherapy demands continuous scrutiny of existing treatments to refine strategies towards precision medicine. Studies like this bridge the gap between randomized trial evidence and real-world application, offering nuanced perspectives that can reshape clinical guidelines and optimize patient care.

Subject of Research: Comparative effectiveness of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes.

Article Title: Comparative Cardiovascular and Renal Outcomes of Liraglutide, Semaglutide, and Dulaglutide Initiators Among Veterans With Diabetes.

News Publication Date: Information not provided.

Web References: Not provided.

References: (doi:10.1001/jamanetworkopen.2025.37297)

Image Credits: Not applicable.

Keywords: Type 2 diabetes, cardiovascular disorders, kidney, medications, risk factors, randomization, diabetes.

The underrepresentation of older adults in clinical trials has been an enduring issue. With many chronic diseases, including obesity, impacting this age group disproportionately, it is vital to understand their unique physiological responses to new medications. As healthcare providers continue to grapple with the complexities of treating obesity in an aging population, insights from studies analyzing GLP-1RAs and GIP/GLP-1RAs are more crucial than ever. Yet, this research often overlooks older adults, leaving a vast chasm of knowledge and potentially jeopardizing health outcomes.

The concern is particularly pronounced given the increasing prevalence of obesity among older populations. Age-related physiological changes can significantly alter the pharmacokinetics and pharmacodynamics of medications. Factors such as decreased renal function, altered body composition, and polypharmacy can influence how drugs are distributed and metabolized in older adults. This indicates that without proper data from older age groups, the clinical efficacy and safety of these therapeutic agents remain poorly understood, compromising treatment strategies based on a one-size-fits-all approach.

Moreover, the implications of this exclusion extend beyond clinical outcomes. They also pertain to regulatory and reimbursement policies that heavily rely on data drawn from trials that do not include a representational segment of the population. As a result, healthcare providers may face uncertainty when prescribing these medications to older adults, leading to potential disparities in access to effective obesity treatments.

Another critical aspect is the notion of informed consent, which is paramount in all clinical trials. The hesitance to include older adults often stems from concerns related to their cognitive and physical capacity to provide informed consent. However, this is a narrow perspective that fails to account for the increasing population of older adults who are not only able but willing to participate in clinical trials. Furthermore, various strategies can be implemented to ensure that older adults are adequately supported and informed throughout the research process.

Additionally, the social and emotional ramifications of obesity in older adults cannot be overstated. Beyond the physical health challenges, the social stigma regarding obesity often disproportionately affects older populations, influencing mental health and self-esteem. By excluding these individuals from obesity treatment trials, researchers inadvertently contribute to the silence surrounding the specific needs and experiences of older adults living with obesity.

The dire need for inclusive clinical trials is not merely an academic exercise; it is a public health obligation. The rising tide of obesity among older populations demands immediate attention and action, encouraging researchers to rethink their recruitment strategies. By promoting inclusivity, researchers can better understand the multidimensional effects of obesity treatments on older adults, ultimately leading to more targeted therapies.

Furthermore, the potential for GLP-1RAs and GIP/GLP-1RAs to influence outcomes in older adults goes beyond just weight loss. Emerging evidence suggests that these agents may offer additional benefits like improved cardiovascular health and glycemic control, both of which are vital in managing multimorbidity in older patients. The paucity of data leaves older adults at a disadvantage, as the rest of the population reaps the benefits of these groundbreaking treatments.

As medicine moves forward in the age of personalized care, tailoring treatments to individuals based on comprehensive, representative data becomes increasingly paramount. The continued exclusion of older adults from pivotal trials may stunt the development of nuanced treatment strategies designed to meet the unique needs of this demographic. It is imperative that the clinical research community takes an ethical stance to ensure that all age groups are represented.

The discourse surrounding inclusivity in clinical trials is becoming more prominent in recent years, driven by organizations advocating for equitable research practices. The future of obesity treatment relies on an understanding that encompasses a wide range of experiences and physiological responses, including those of older adults who are often sidelined.

Researchers must also engage with older adults directly, gathering qualitative data on their needs, preferences, and experiences with obesity treatments. Such engagement can guide investigators in designing trials that not only include older individuals but are also relevant and applicable to their everyday lives. This can foster an environment where older adults feel valued and empowered in their health care journey.

In summary, the exclusion of older adults from obesity treatment pivotal trials is a pressing issue that demands urgent attention. Researchers, clinicians, and regulators must collaborate to bridge the gap between innovative obesity therapeutics and the older adult population. By prioritizing inclusion, we can pave the way for a future where effective treatments are accessible to all, regardless of age.

What remains vital in this conversation is the recognition that addressing the complexities of obesity treatment in older adults is not merely about expanding trial participants; it’s a crucial step towards equitable health care. Giving voice to older adults in research will ultimately enhance the understanding of treatment effectiveness, improve clinical outcomes, and develop a roadmap for future investigations that resonate with the needs of a diverse patient population.

The time has come for the medical community to act decisively and inclusively, ensuring older adults are no longer on the periphery of obesity treatment discussions. The need for comprehensive, representative research has never been clearer, and it’s an obligation that should be at the forefront of everyone involved in health care.

Subject of Research: The exclusion of older adults from obesity treatment pivotal trials of GLP-1RAs and GIP/GLP-1RAs.

Article Title: Exclusion of Older Adults from Obesity Treatment Pivotal Trials of GLP-1RAs and GIP/GLP-1RAs.

Article References:

Chen, A.S., Liang, Y., Lipska, K.J. et al. Exclusion of Older Adults from Obesity Treatment Pivotal Trials of GLP-1RAs and GIP/GLP-1RAs.
J GEN INTERN MED (2025). https://doi.org/10.1007/s11606-025-09769-z

Image Credits: AI Generated

DOI: 10.1007/s11606-025-09769-z

Keywords: Obesity treatment, GLP-1 receptor agonists, older adults, clinical trials, health equity.